BRPI0412596A - derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3 - Google Patents

derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3

Info

Publication number
BRPI0412596A
BRPI0412596A BRPI0412596-7A BRPI0412596A BRPI0412596A BR PI0412596 A BRPI0412596 A BR PI0412596A BR PI0412596 A BRPI0412596 A BR PI0412596A BR PI0412596 A BRPI0412596 A BR PI0412596A
Authority
BR
Brazil
Prior art keywords
optionally substituted
polyhaloc
alkylcarbonyl
alkyl
alkyloxycarbonyl
Prior art date
Application number
BRPI0412596-7A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Christopher John Love
Ludwig Paul Cooymans
Nele Vandermaesen
Peter Jacobus Johan Buijnsters
Marc Willems
Werner Constant Joha Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0412596A publication Critical patent/BRPI0412596A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE TRIAZOLOPIRIMIDINA COMO INIBIDORES DE GLICOGêNIO SINTASE CINASE 3". A presente invenção refere-se a um composto da fórmula (I), um N-óxido, um sal de adição farmaceuticamente aceitável, uma amina quaternária e uma forma estereoquimicamente isomérica deste, em que o anel A representa fenila, piridila, pirimidinila, piridazinila ou pirazinila; R¬ 1¬ representa hidrogênio; arila; formila; C~ 1~-6alquilcarbonila; C~ 1~-6alquila; C~ 1~- 6alquiloxícarbonila; C~ 1~-6alquila substituída com formila, C~ 1~-6alquilcarbonila, C~ 1~6alquiloxicarbonila, C~ 1~-6alquilcarbonilóxi; OU C~ 1~-6alquiloxiC~ 1~-6alquilcarbonila opcionalmente substituída com C~ 1~-6alquiloxicarbonila; X representa uma ligação direta; -(CH~ 2~)n~ 3~- Ou -(CH~ 2~)n~ 4~-X~ 1a~-~X~ 1b~-; R¬ 2¬ representa C~ 3~-7Cicloalquila; fenila; um heterociclo monocíclico de 4, 5, 6 ou 7 membros contendo pelo menos um heteroátomo selecionado de 0, S ou N; benzoxazolila ou um radical da fórmula (a~ -1~), em que o dito substituinte de R¬ 2¬ pode opcionalmente ser substituído; R¬ 3¬ representa halo; hidróxi; C~ 1~-6alquila opcionalmente substituída; C~ 2~-6alquenila ou C~ 2~-6alquinila, cada uma opcionalmente substituída; polihaloC~ 1~-6alquila opcionalmente substituída; C~ 1~-6alquilóxi opcionalmente substituída; polihaloC~ 1~-6alquilóxi opcionalmente substituído; C~ 1~-6alquiltio; polihaloC~ 1~-6alquiltio; C~ 1~-ralquil-oxicarbonila; C~ 1~-6alquilcarbonilóxi; C~ 1~6alquilcarbonila; polihaloC~ 1~-6alquilcarbonila; ciano; carboxila; arilóxi; ariltio; arilcarbonila; NR¬ 6b¬R¬ 7b¬C(=O)-NR¬ 6b¬R¬ 7b¬-NR¬ 5¬-C(=O)-R¬ 5¬; -S(=O)~ n1~-R¬ 8a¬; -NR¬ 5¬S(=O)~ n1~-R¬ 8a¬; -NR¬ 5¬-S(=O)~ n1~-R¬ 8a¬, -S-CN; -NR¬ 5¬-CN; R¬ 4¬ representa hidrogênio; halo; hidróxi; C¬ 1~-4alquila opcionalmente substituída; C~ 2~-4alquenila ou C~ 2-~ 4alquinila, cada uma opcionalmente substituída; polihaloC~ 1~-3alquila; C~ 1~4alquilóxi opcionalmente substituído; polihalo-C~ 1~-3alquilóxi; C~ 1~-4alquiltio; polihaloC~ 1~-3alquiltio; C~ 1~-4alquiloxicarbonila; C~ 1~-4alquilcarbonilóxi; C~ 1~4alquilcarbonila; polihaloC~ 1~-4alquil-carbonila; nitro; ciano; carboxila; NR¬ 10¬R¬ 11¬; C(=O)NR¬ 10¬R¬ 11¬; -NR¬ 5¬-C(=O)-NR¬ 10¬R¬ 11¬; -NR¬ 5¬-C(=O)-R¬ 5¬; -S(=O)~ n1~-R¬ 12¬; -NR¬ 5¬S(=O)~ n1~-R¬ 12¬; -S-CN; -NR¬ 5¬-CN; seu uso, composições farmacêuticas compreendendo e processos para sua preparação.
BRPI0412596-7A 2003-07-16 2004-07-12 derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3 BRPI0412596A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350310 2003-07-16
PCT/EP2004/051455 WO2005012307A1 (en) 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0412596A true BRPI0412596A (pt) 2006-09-19

Family

ID=34112425

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412596-7A BRPI0412596A (pt) 2003-07-16 2004-07-12 derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3

Country Status (26)

Country Link
US (2) US7560458B2 (pt)
EP (1) EP1658292B1 (pt)
JP (1) JP2009514782A (pt)
KR (1) KR20060120393A (pt)
CN (1) CN100404536C (pt)
AP (1) AP2006003486A0 (pt)
AR (1) AR045698A1 (pt)
AT (1) ATE370142T1 (pt)
AU (1) AU2004260738B2 (pt)
BR (1) BRPI0412596A (pt)
CA (1) CA2531333A1 (pt)
DE (1) DE602004008303T2 (pt)
DK (1) DK1658292T3 (pt)
EA (1) EA010109B1 (pt)
ES (1) ES2290754T3 (pt)
IL (1) IL173139A (pt)
JO (1) JO2460B1 (pt)
MX (1) MXPA06000540A (pt)
NO (1) NO20060678L (pt)
NZ (1) NZ545058A (pt)
PA (1) PA8607001A1 (pt)
PL (1) PL1658292T3 (pt)
PT (1) PT1658292E (pt)
TW (1) TW200524935A (pt)
WO (1) WO2005012307A1 (pt)
ZA (1) ZA200600385B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
DK1658292T3 (da) * 2003-07-16 2007-11-12 Janssen Pharmaceutica Nv Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
BRPI0413616B8 (pt) * 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
EP2145888A1 (en) * 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) * 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
AU2012367141B2 (en) * 2012-01-28 2016-12-22 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
JP6049768B2 (ja) 2012-03-07 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ トリアゾロピラジン誘導体
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
ES2637721T3 (es) 2013-05-06 2017-10-16 Merck Patent Gmbh Macrociclos como inhibidores de quinasa
EP3226861A2 (en) * 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Compounds for treating cystic fibrosis
US11370793B2 (en) 2015-08-27 2022-06-28 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
EP1347972A1 (en) * 2000-12-19 2003-10-01 Smithkline Beecham Plc Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
DK1658292T3 (da) * 2003-07-16 2007-11-12 Janssen Pharmaceutica Nv Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer

Also Published As

Publication number Publication date
US20060205721A1 (en) 2006-09-14
ZA200600385B (en) 2007-05-30
MXPA06000540A (es) 2006-03-30
EA010109B1 (ru) 2008-06-30
TW200524935A (en) 2005-08-01
CA2531333A1 (en) 2005-02-10
PA8607001A1 (es) 2005-05-10
AU2004260738A1 (en) 2005-02-10
EA200600258A1 (ru) 2006-06-30
AP2006003486A0 (en) 2006-02-28
DE602004008303T2 (de) 2008-05-08
DK1658292T3 (da) 2007-11-12
US20090036471A1 (en) 2009-02-05
US7560458B2 (en) 2009-07-14
PT1658292E (pt) 2007-10-25
NZ545058A (en) 2008-05-30
EP1658292A1 (en) 2006-05-24
KR20060120393A (ko) 2006-11-27
DE602004008303D1 (de) 2007-09-27
AR045698A1 (es) 2005-11-09
ES2290754T3 (es) 2008-02-16
WO2005012307A1 (en) 2005-02-10
CN1823068A (zh) 2006-08-23
IL173139A (en) 2010-04-29
AU2004260738B2 (en) 2009-07-16
JP2009514782A (ja) 2009-04-09
EP1658292B1 (en) 2007-08-15
IL173139A0 (en) 2006-06-11
ATE370142T1 (de) 2007-09-15
JO2460B1 (en) 2009-01-20
CN100404536C (zh) 2008-07-23
PL1658292T3 (pl) 2008-01-31
NO20060678L (no) 2006-02-10

Similar Documents

Publication Publication Date Title
BRPI0412596A (pt) derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3
BR0213791A (pt) Derivados de amida como inibidores de glicogênio sintase quinase 3-beta
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
BR0213792A (pt) Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
EA200600257A1 (ru) Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR037235A1 (es) Derivados de sulfonamida, medicamentos que los contienen y el uso de dichos derivados para la preparacion de medicamentos
AR087288A1 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
BRPI0407329A (pt) Derivados de pirimidina para a prevenção de infecção de hiv
AR062292A1 (es) Derivados de pirrolo (2,3 d) pirimidina como inhibidor de pi3k, composiciones farmaceuticas y usos de los mismos
EA200970655A1 (ru) 6-замещенные пиримидины, ингибирующие вич
AR085099A1 (es) Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas
CO6420344A2 (es) Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map)
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
CY1110502T1 (el) Αντιμυκητικες 4-υποκατεστημενες 5,6-διϋδρο-4η-πυρρολο[1,2-α][1,4]βενζοδιαζεπινες
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
AR044883A1 (es) Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos
AR060496A1 (es) Inhibidores transportadores de serotonina y nk-1
AR037506A1 (es) Compuestos derivados de 4-fenil-4-[1h-imidazol-2-il]piperidina sustituida, sus profarmacos, composiciones farmaceuticas que comprenden dichos compuestos derivados, y uso de dichos compuestos derivados o composiciones farmaceuticas para la elaboracion de medicamentos
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012.